181 related articles for article (PubMed ID: 9225960)
1. Alternative formulations of paclitaxel.
Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
[TBL] [Abstract][Full Text] [Related]
2. Progress in the development of alternative pharmaceutical formulations of taxanes.
Nuijen B; Bouma M; Schellens JH; Beijnen JH
Invest New Drugs; 2001 May; 19(2):143-53. PubMed ID: 11392448
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and its formulations.
Singla AK; Garg A; Aggarwal D
Int J Pharm; 2002 Mar; 235(1-2):179-92. PubMed ID: 11879753
[TBL] [Abstract][Full Text] [Related]
4. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
[No Abstract] [Full Text] [Related]
5. Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
Chowdhury MR; Moshikur RM; Wakabayashi R; Tahara Y; Kamiya N; Moniruzzaman M; Goto M
Mol Pharm; 2018 Jun; 15(6):2484-2488. PubMed ID: 29762034
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.
Heney M; Alipour M; Vergidis D; Omri A; Mugabe C; Th'ng J; Suntres Z
Can J Physiol Pharmacol; 2010 Dec; 88(12):1172-80. PubMed ID: 21164564
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
8. Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxel-cholesterol complex.
Xia XJ; Guo RF; Liu YL; Zhang PX; Zhou CP; Jin DJ; Wang RY
Chem Pharm Bull (Tokyo); 2011; 59(3):321-6. PubMed ID: 21372412
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
[TBL] [Abstract][Full Text] [Related]
10. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.
Crosasso P; Ceruti M; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):19-30. PubMed ID: 10640577
[TBL] [Abstract][Full Text] [Related]
12. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
Lundberg BB
Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
[TBL] [Abstract][Full Text] [Related]
14. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
Singh S; Dash AK
Crit Rev Ther Drug Carrier Syst; 2009; 26(4):333-72. PubMed ID: 20001890
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.
Dhanikula AB; Singh DR; Panchagnula R
Curr Drug Deliv; 2005 Jan; 2(1):35-44. PubMed ID: 16305406
[TBL] [Abstract][Full Text] [Related]
17. Current development in the formulations of non-injection administration of paclitaxel.
Du X; Khan AR; Fu M; Ji J; Yu A; Zhai G
Int J Pharm; 2018 May; 542(1-2):242-252. PubMed ID: 29555439
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of paclitaxel-containing liposomes.
Holvoet C; Vander Heyden Y; Lories G; Plaizier-Vercammen J
Pharmazie; 2007 Feb; 62(2):126-32. PubMed ID: 17341033
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
Li Y; Chen N; Palmisano M; Zhou S
Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
